Unlike GnRH agonists and older GnRH antagonists, which are peptides and first-generation GnRH modulators, elagolix is not a GnRH analogue as it is not structurally related to GnRH. Elagolix was the first second-generation and orally active GnRH modulator to be introduced for medical use. The introduction of elagolix in the United States and Canada was followed by that of relugolix (brand name Relumina), the next second-generation GnRH antagonist, in Japan in January 2019. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses
Elagolix is used in the treatment of moderate to severe pain associated with endometriosis in premenopausal women. Endometriosis is a condition in which the endometrium, the inner lining of the uterus, grows outside of the uterus into surrounding tissues and causes symptoms such as pelvic pain and infertility. Around 10% of women may be affected by endometriosis. Elagolix significantly decreases symptoms of dysmenorrhea (menstrual pelvic pain), non-menstrual pelvic pain, and dyspareunia (pain during sexual intercourse) in women with endometriosis. The medication is used at a lower dosage of 150 mg once per day or at a higher dosage of 200 mg twice per day, depending on the severity of symptoms.The effectiveness of elagolix in the treatment of symptoms of endometriosis was demonstrated in the 6-month Elaris Endometriosis I and II (EM-I and EM-II) phase III clinical trials.
Dyssomnias are a broad classification of sleeping disorders involving difficulty getting to sleep, remaining asleep, or of excessive sleepiness. Dyssomnias are primary disorders of initiating or maintaining sleep or of excessive sleepiness and are characterized by a disturbance in the amount, quality, or timing of sleep. Patients may complain of difficulty getting to sleep or staying asleep, intermittent wakefulness during the night, early morning awakening, or combinations of any of these. Transient episodes are usually of little significance. Stress, caffeine, physical discomfort, daytime napping, and early bedtimes are common factors. Types
There are over 31 recognized kinds of dyssomnias. The major three groups, along with the group types, include:: 15 Intrinsic sleep disorders: 15 
idiopathic hypersomnia,
narcolepsy,
periodic limb movement disorder,
restless legs syndrome,
obstructive sleep apnea,
central sleep apnea syndrome,
sleep state misperception,
psychophysiologic insomnia,
recurrent hypersomnia,
post-traumatic hypersomnia,
central alveolar hypoventilation syndrome,
Extrinsic sleep disorders – 13 disorders recognized, including: 16 alcohol-dependent sleep disorder,
food allergy insomnia,
inadequate sleep routine. Circadian rhythm sleep disorders, both intrinsic and extrinsic – 6 disorders recognized, including: 16 advanced sleep phase syndrome,
delayed sleep phase syndrome,
jetlag,
shift work sleep disorder. See also
Parasomnia
Sleep problems in women
Somnolence

References


== External links ==